WO2020084346A1 - Uso de recambio plasmático de bajo volumen para el tratamiento de la enfermedad de alzheímer en etapas temprana y moderada - Google Patents
Uso de recambio plasmático de bajo volumen para el tratamiento de la enfermedad de alzheímer en etapas temprana y moderada Download PDFInfo
- Publication number
- WO2020084346A1 WO2020084346A1 PCT/IB2019/001145 IB2019001145W WO2020084346A1 WO 2020084346 A1 WO2020084346 A1 WO 2020084346A1 IB 2019001145 W IB2019001145 W IB 2019001145W WO 2020084346 A1 WO2020084346 A1 WO 2020084346A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- lvpe
- composidon
- disease
- albumin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the medical sector, in particular to the use of low-volume plasma exchange for the treatment of Alzheimer's disease in early and moderate stages.
- AD Alzhelmer's Disease
- NFT Inrane Neurofibrillary Tangles
- Ab amyloid plaques formed from the extracellular aggregates of b-amylolde (Ab) peptides
- amyloid precursor protein APP
- secretases secretases
- APP is cleaved by b-secretase to release a soluble N-terminal fragment (sAPP b, for its English g s) and a membrane-bound C-terminal fragment (C99), which in turn is cleaved by y-secrelase to produce the intracellular domain of the soluble amyloid precursor protein (AICD) and a heterogeneous generation of peptides Ab insoluble, with Ab1 -40 and Ab1 -42 being the most common.
- AICD soluble amyloid precursor protein
- the hydrophobic properties of Ab facilitate the formation of amyloid plaques in the brain, particularly Ab1 -42 because it is less soluble and more toxic relative to Ab1-40.
- APP is constitutively cleaved by the o-secretase within the Ab sequence; therefore, the formation of amylddogenic Ab is avoided.
- AD Alzheimer's disease
- therapies for the treatment of AD including cholinesterase inhibitors and arctic N-metll-D-asp acid receptor antagonists (NMDA).
- NMDA arctic N-metll-D-asp acid receptor antagonists
- LVPE low volume
- IVIG intravenous venous immunoglubulin
- ADCS-ADL Inventory the Activities of the Cooperative Studies of Alzheimer's Disease of Daily Living (ADCS-ADL Inventory) (Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, and others An Inventory to Assess Actlvi ties of Daly Uving for Clinical Triais in Aizheimer's Disease. Akhaimer O ⁇ s Assoc Disord. 1997; 11: 33 9) in relatives with mild and moderate AE were improved. Surprisingly, this improvement is greater in patients with moderate AD.
- the LVPE treatment regimen requires smaller volumes than traditional therapeutic plasma exchange, a shorter duration time, and a single venipuncture, reducing patient discomfort and reducing the adverse effects of treatment.
- FIG 1 is a schematic view of the interventions of the diphnic study according to the present Invention (TPE: therapeutic plasma exchange; LVPE: low volume plasma exchange; F: Flebogamma 5% DIF [inrnunoglobullna by intravenous vfa]; A: Albumin 5% -20% (albumin]; S: sham treatment; B: final visit; IV: intermediate visit: VF: final visit)
- TPE therapeutic plasma exchange
- LVPE low volume plasma exchange
- F Flebogamma 5% DIF [inrnunoglobullna by intravenous vfa]
- A Albumin 5% -20% (albumin]
- S sham treatment
- B final visit
- IV intermediate visit: VF: final visit
- Figure 2 is a graph showing the change in ADAS-Cog with respect to the baseline over time for the four groups of relatives included in the clinical study.
- Figure 3 is a graph showing the change in ADCS-ADL with respect to the baseline over time in the four groups of patients included in the clinical study.
- Figure 4 is a graph showing the change of ADAS-Cog with respect to the baseline over time in all treated patients compared to the control group.
- Figure 5 is a graph showing the change of ADCS-ADL with respect to the baseline over time in all treated patients compared to the control group.
- Figure 6 is a graph showing the change of ADAS-Cog with respect to the baseline in time of relatives treated with mild AD (MMSE 22-26) compared to the control group.
- Figure 7 is a graph showing the change in ADCS-ADL with respect to the baseline over time for patients treated with mild AD (MMSE 22-26) compared to the control group.
- Figure 8 is a graph showing the change in ADAS-Cog with respect to the baseline over time for patients treated with moderate AD (MMSE 18-21) compared to the control group.
- Figure 9 is a graph showing the change in ADCS-ADL with respect to the baseline over time for patients treated with moderate AD (MMSE 18-21) compared to the control group.
- Figure 10 is a graph showing the change of ADCS-ADL with respect to the baseline in time of patients treated with moderate AD (MMSE 18-21) of the three treated groups compared to the control group.
- Figure 11 is a graph showing Abn 42 levels in SCI at the end of each of the two treatment periods in all relatives (A), in patients with mild AD (MMSE 22-26) (B) and with Moderate EA (MMSE 18-21) (C).
- Figure 12 is a graph showing the levels of T-tau (A) and P-tau (B) in SCI at the end of each of the two treatment periods in patients with moderate AD (MMSE 18-21).
- the present invention relates to the use of human albumin at a concentration between 5% (w / v) and 25% (w / v) for the treatment of mild and moderate Alzheimer's Disease (AD) by means of replacement. low volume plasma (LVPE).
- LVPE low volume plasma
- low volume plasma exchange refers to plasma exchange treatments with blood volumes between 600 mL - 900 mL.
- 'mild AD' refers to individuals who have a Miri-Mental State Examination (MMSE) score of 22-26 at the initial visit (Folstein MF. Folstein SE, McHugh PR. Mlnl-mental State, A practical method for gradlng the cognitive State of patlents for the dinidan. J Psychiatr Res 1975; 12: 189-98).
- MMSE Miri-Mental State Examination
- the term “moderate AD” refers to individuals who they have a MMSE score on the indal visit from 18 to 21.
- the treatment of the present invention further comprises intravenous immunoglobulin administration (IVIG).
- IVIG intravenous immunoglobulin administration
- the treatment of the present invention further comprises intravenous immunoglobulin administration (IVIG).
- IVIG intravenous immunoglobulin administration
- each LVPE treatment involves automated plasma exchange using a single venopundon.
- the device may induce an inlet port to drain the complete blood from the applicant, means to separate the plasma from the cellular components of the blood, and means to return the cellular components of the blood through the inlet port from where the cellular components of the blood leave the device.
- the means for separating plasma from cellular components of blood are centrifuge stockings (ie, a centrifuge). More preferably, the means for separating the plasma from the cellular components of the blood are filtering means (ie, a filter such as that used in the double filtering plasma exchange).
- the treatment regimen comprises administering three or more times one LVPE, four or more times one LVPE, one or more times one LVPE, six or more times one LVPE, seven or more times one LVPE, eight or more times one LVPE, nine or more times one LVPE, or ten or more times one LVPE, eleven or more times one LVPE, or twelve or more times one LVPE to the relative.
- pre-treatment of convendonal plasma exchange can be carried out prior to the tralation regimen.
- said TPE regimen can be carried out at a frequency of 1 TPE per week, more preferably for at least 6 weeks.
- the term 'PTE' refers to plasma exchange in which 2,500 to 3,000 mL of the relative's plasma is replaced with the same volume of a replacement fluid.
- each subsequent treatment of LVPE is carried out from 10 to 45 days after pretreatment
- each post-treatment of LVPE is carried out 15 to 35 days after pretreatment, more preferably each post-treatment of LVPE is carried out 30 days after pretreatment.
- Between 10 g and 40 g of albumin are used for replacement in each LVPE treatment, preferably between 20 g and 40 g of albumin in each LVPE treatment.
- the study in Africa was a multi-center, randomized, blind, placebo-controlled trial of parallel groups with a total of 498 relatives with mild and moderate AD from 41 centers, 19 in Spain and 22 in United States.
- PE plasma exchange treatment
- Placebo a control group
- Patients in the control group underwent sham PE using a noninvasive (sham) procedure that mimicked plasma turnover but did not replace fluid or administer albumin or IVIG.
- Patients, caregivers, and evaluators were unaware of the therapy received.
- a unique code was used for the anonymity of the patients.
- MRI was used during the selection period to rule out any finding that could affect patient safety, such as microbleeds.
- the intervention regimen included a 6-week first stage of intensive treatment with one conventional therapeutic plasma exchange (TPE) session per week, where all patients assigned to any of the treatment groups followed the same regimen. of treatment, followed by a 12-month second stage of maintenance treatment with one session of plasma bay volume (LVPE) per month, as summarized in Figure 1.
- TPE therapeutic plasma exchange
- LVPE plasma bay volume
- LVPE 5% Albutein®
- Albutein® 20% GRIFOLS, SA
- TPE was performed using a commercial continuous flow cell separator with kissed technology in centrifugation or filtration.
- a peripheral (eg, radial / ulnar vein) or central (eg, sub avia / jugular vein) access was used depending on the patient's individual characteristics.
- Implantation and maintenance of venous access were carried out according to the standard procedures used in each center and the correct placement of a central catheter was always confirmed with a chest x-ray.
- the volume of plasma withdrawn and replaced depended on the characteristics of the patient (ie, sex, height, weight, and hematocrit). It was approximately 35-45 mUkg, corresponding to a volume of 2500-3000 mL.
- LVPE was performed through a peripheral line using a prototype apheresis device based on the Auto-C TM device (Fenwal Inc, Lake Zurich, IL, USA) or the Aurora 1 * 1 device (Fresenius Kabi, Bad Homburg, Germany), the new version of Auto-C TM.
- the volume of plasma withdrawn was similar to that of a plasma donation (650-880 ml) and depended on the weight of the patient.
- the volume of albumin infused was consistent with the treatment arm as previously described. Normal saline was used when there was a negative balance between the volume of plasma withdrawn and the albumin infused.
- the tip of a cut catheter was sewn onto an adhesive colostomy patch (acting as a "second skin") that was placed in the subdavicular or jugular region.
- the patch with the stitched catheter tip was covered with a gauze dressing and an adhesive film.
- the corlated catheter B had similar characteristics to the catheters used in the treatment group.
- a conventional PE device was loaded with an iron-colored saline that mimicked intravenous plasma, operating in a closed fashion without any exchange of tpe between the device and the patient.
- a prototype based on Autopheresis-C or Aurora provided an apparently realistic working state, in which expired human blood from a local blood bank circulated in a closed fashion.
- the co-priming efficacy variables were: i) the change from the beginning in the cognitive scores, measured with the ADAS-Cog scale; and II) the change with respect to the baseline in the functional scores measured by the ADCS-ADL inventory. In both cases 6 measurements were made: one in week -3, -2 or -1 (baseline), one in week 7-8 (end of intensive treatment period) and one in months 6, 9, 12 and 14 (end of maintenance treatment period). The final point for the primary efficacy analysis was at fourteen months (see Figure 1).
- the ADAS-Cog is an instrument specifically designed to assess the severity of fundamental cognitive and behavioral disturbances that are characteristic of AD patients. Functional ability is assessed using the ADCS-ADL test, which as outlined above provides detailed descriptions of each activity and provides the Reporter with descriptions of the observed behaviors or acdons.
- PE is a safe technique that can induce expected and therefore preventable and controllable adverse reactions (by temple, hypocal stinging, hypotension).
- the vital signs and the parameters of the laboratory tests were controlled more frequently than in the typical environment.
- relatives had to remain in the center before and after the PE procedure for longer than usual and the caregiver was present with the exception of the actual procedure to maintain their blindness.
- agitated or anxious patients were accompanied by the caregiver during the procedure to alleviate the relative's anxiety.
- the blind protocol was maintained for both the relative and the caregiver.
- the primary criterion for the safety assessment was the percentage of TPE and LVPE procedures (including albumin infusion and IVIQ) associated with at least one adverse event (AE) that could be related to the procedure. study (adverse reaction).
- vital signs blood pressure, heart rate, respiratory rate, and body temperature
- parameters of laboratory tests blood cell count, platelet count, prothrombin time [Fast], activated partial thromboplastin time [aPTT ], flbrinogen, total protein, and drop
- the AE were coded according to the World Health Organization (WHO) classification of adverse events (current version of MeDRA), and were described by a synonym (Lower level term) and the affected organ / system, the intensity, causality and severity.
- WHO World Health Organization
- Figures 4 and 5 show a graph in which the treated groups were grouped and compared with the control group. A change was observed with respect to the baseline of 2.1 and 3.5 of ADAS-Cog and ADCS-ADL, respectively.
- Figure 1 1 A shows that APMZ levels in the LCE decrease in all patients treated with therapeutic plasma exchange (TPE) and low-volume plasma exchange (LVPE) compared to untreated patients (placebo group) (N-299 ).
- Figure 11B shows that Abi-ti levels in LCE decrease in patients with mild AD (MMSE 22-26) treated with TPE compared to untreated patients (N-145).
- Figure 11B shows that Ab, or SCI levels are maintained in patients with mild AD (MMSE 22-26) treated with LVPE compared to untreated patients (N-145).
- Figure 1C shows that Aflv t a levels in SCI decrease in patients with moderate AD (MMSE 16-21) treated with TPE and LVPE compared to untreated patients (N-154).
- Figure 12 shows that the levels of T-tau (Figure 12A) and P-tau (Figure 12B) in LCE decrease in patients with moderate AD (MMSE 18-21) treated with TPE and LVPE compared to untreated patients (group placebo) (N-154).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3112452A CA3112452A1 (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
BR112021004473-6A BR112021004473A2 (pt) | 2018-10-25 | 2019-10-23 | uso de troca de plasma de baixo volume para o tratamento da doença de alzheimer em estágios iniciais e moderados |
US17/275,452 US20220047680A1 (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
SG11202102437PA SG11202102437PA (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for the treatment of alzheimer’s disease in early and middle stages |
MX2021002936A MX2021002936A (es) | 2018-10-25 | 2019-10-23 | Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada. |
AU2019365514A AU2019365514A1 (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
KR1020217007276A KR20210086604A (ko) | 2018-10-25 | 2019-10-23 | 조기 및 중기의 알츠하이머병의 치료를 위한 저용적 혈장 교환의 용도 |
EP19820861.3A EP3871686A1 (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
JP2021513446A JP2022503682A (ja) | 2018-10-25 | 2019-10-23 | 初期及び中間期のアルツハイマー病を治療するための低容量血漿交換の使用 |
CN201980059223.6A CN112672756A (zh) | 2018-10-25 | 2019-10-23 | 低容量血浆置换用于治疗早期和中期的阿尔茨海默病的用途 |
IL281395A IL281395A (en) | 2018-10-25 | 2021-03-10 | Treatment of early stages of Alzheimer's by replacing a small volume of plasma |
US18/543,196 US20240115665A1 (en) | 2018-10-25 | 2023-12-18 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18202720.1A EP3643319A1 (en) | 2018-10-25 | 2018-10-25 | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
EP18202720.1 | 2018-10-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/275,452 A-371-Of-International US20220047680A1 (en) | 2018-10-25 | 2019-10-23 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
US18/543,196 Division US20240115665A1 (en) | 2018-10-25 | 2023-12-18 | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020084346A1 true WO2020084346A1 (es) | 2020-04-30 |
Family
ID=64308472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/001145 WO2020084346A1 (es) | 2018-10-25 | 2019-10-23 | Uso de recambio plasmático de bajo volumen para el tratamiento de la enfermedad de alzheímer en etapas temprana y moderada |
Country Status (16)
Country | Link |
---|---|
US (2) | US20220047680A1 (es) |
EP (2) | EP3643319A1 (es) |
JP (1) | JP2022503682A (es) |
KR (1) | KR20210086604A (es) |
CN (1) | CN112672756A (es) |
AR (1) | AR116918A1 (es) |
AU (1) | AU2019365514A1 (es) |
BR (1) | BR112021004473A2 (es) |
CA (1) | CA3112452A1 (es) |
CL (1) | CL2021000593A1 (es) |
IL (1) | IL281395A (es) |
MX (1) | MX2021002936A (es) |
SG (1) | SG11202102437PA (es) |
TW (1) | TWI831851B (es) |
UY (1) | UY38426A (es) |
WO (1) | WO2020084346A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240216477A1 (en) * | 2021-04-30 | 2024-07-04 | Grifols Worldwide Operations Limited | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment |
US12005172B2 (en) | 2022-05-31 | 2024-06-11 | Lyfspn, Inc. | Compositions and methods for plasmapheresis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2332846B1 (es) * | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
KR102460465B1 (ko) * | 2014-04-29 | 2022-10-27 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병(ad)의 치료 및 예방 |
-
2018
- 2018-10-25 EP EP18202720.1A patent/EP3643319A1/en not_active Withdrawn
-
2019
- 2019-10-23 TW TW108138255A patent/TWI831851B/zh active
- 2019-10-23 KR KR1020217007276A patent/KR20210086604A/ko active Search and Examination
- 2019-10-23 US US17/275,452 patent/US20220047680A1/en not_active Abandoned
- 2019-10-23 SG SG11202102437PA patent/SG11202102437PA/en unknown
- 2019-10-23 EP EP19820861.3A patent/EP3871686A1/en active Pending
- 2019-10-23 UY UY0001038426A patent/UY38426A/es unknown
- 2019-10-23 MX MX2021002936A patent/MX2021002936A/es unknown
- 2019-10-23 AU AU2019365514A patent/AU2019365514A1/en active Pending
- 2019-10-23 AR ARP190103021A patent/AR116918A1/es unknown
- 2019-10-23 JP JP2021513446A patent/JP2022503682A/ja active Pending
- 2019-10-23 WO PCT/IB2019/001145 patent/WO2020084346A1/es unknown
- 2019-10-23 BR BR112021004473-6A patent/BR112021004473A2/pt unknown
- 2019-10-23 CN CN201980059223.6A patent/CN112672756A/zh active Pending
- 2019-10-23 CA CA3112452A patent/CA3112452A1/en active Pending
-
2021
- 2021-03-10 IL IL281395A patent/IL281395A/en unknown
- 2021-03-10 CL CL2021000593A patent/CL2021000593A1/es unknown
-
2023
- 2023-12-18 US US18/543,196 patent/US20240115665A1/en active Pending
Non-Patent Citations (2)
Title |
---|
BOADA ET AL: "Changes in cognitive status of Alzheimer's disease patients treated with plasma exchange and replacement with human albumin plus immunoglobulin. Interim results of the AMBAR trial.", ALZHEIMER DEMENTIA, vol. 12, 2016 - 2016, pages P419 - P420, XP002790387 * |
BOADA M; RAMOS-FERNÁNDEZ E; GUIVERNAU B; MUÑOZ F J; COSTA M; ORTIZ A M; JORQUERA J I; NÚÑEZ L; TORRES M; PÁEZ A: "Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.", NEUROLOGIA, vol. 71, no. 7, 9 July 2014 (2014-07-09) - 9 July 2014 (2014-07-09), pages 473 - 481, XP002790386 * |
Also Published As
Publication number | Publication date |
---|---|
SG11202102437PA (en) | 2021-04-29 |
KR20210086604A (ko) | 2021-07-08 |
AU2019365514A1 (en) | 2021-04-08 |
US20220047680A1 (en) | 2022-02-17 |
EP3871686A1 (en) | 2021-09-01 |
IL281395A (en) | 2021-04-29 |
EP3643319A1 (en) | 2020-04-29 |
TWI831851B (zh) | 2024-02-11 |
BR112021004473A2 (pt) | 2021-05-25 |
UY38426A (es) | 2020-03-31 |
CN112672756A (zh) | 2021-04-16 |
AR116918A1 (es) | 2021-06-30 |
MX2021002936A (es) | 2021-06-15 |
JP2022503682A (ja) | 2022-01-12 |
CL2021000593A1 (es) | 2021-07-30 |
TW202031286A (zh) | 2020-09-01 |
US20240115665A1 (en) | 2024-04-11 |
CA3112452A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boada et al. | Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress | |
US11413308B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
US20240115665A1 (en) | Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease | |
ES2968375T3 (es) | Formulaciones de TPP1 y métodos para tratar la enfermedad CLN2 | |
US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
AU2019306477B2 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
BRPI0804623B1 (pt) | Uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
Sanjari et al. | Visual outcomes of adding erythropoietin to methylprednisolone for treatment of retrobulbar optic neuritis | |
Min et al. | Allogenic umbilical cord blood therapy combined with erythropoietin for patients with severe traumatic brain injury: three case reports | |
ES2954171T3 (es) | Compuestos para su uso en métodos para tratar glaucoma y enfermedades de la retina | |
Bai et al. | Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepato-protective drugs in combination with intravenous ozone without steroids: A case report | |
RU2802628C2 (ru) | Использование плазмафереза малого объема для лечения болезни альцгеймера на ранних и средних стадиях | |
ES2598241T3 (es) | Método y dispositivo para el tratamiento de trastornos del colesterol en la sangre | |
RU2506973C2 (ru) | Способ комплексного лечения возрастной макулярной дегенерации | |
Izidoro et al. | Maintenance fluid therapy in sick children: state of art | |
YUDKIN | Vitamins in treatment and prevention of ocular diseases | |
Lillie | Tryparsamide Treatment of Syphilis of the Central Nervous System: Observations from an Ophthalmologic Standpoint | |
Karsten et al. | O12. 1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL | |
SU1168262A1 (ru) | Способ лечени мигрени | |
Ajibode | Retinopathy of prematurity: a review | |
CN113679709A (zh) | 丁香脂素在制备防治糖尿病肾病药物中的应用 | |
Jean | Glioma of the Retina | |
Pateisky | the electroencephalogram. Changes in Blood Pressure in Ophthalmic Operations.—At the | |
George | Shoes for Children | |
London | Stow-on-the-Wold, SJ STRONG. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19820861 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021513446 Country of ref document: JP Kind code of ref document: A Ref document number: 3112452 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021004473 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019365514 Country of ref document: AU Date of ref document: 20191023 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112021004473 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210310 |
|
ENP | Entry into the national phase |
Ref document number: 2019820861 Country of ref document: EP Effective date: 20210525 |